

**PB 29 of 2024**

National Health (Prescriber Bag Supplies) Determination 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 March 2024

Nikolai Tsyganov

Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

Contents

Part 1—Preliminary 1

1 Name 1

2 Commencement 1

3 Authority 1

4 Definitions 1

5 References to a pharmaceutical benefit that has a drug in a relevant form 2

Part 2—Authorisation of practitioners and maximum quantity (number of units) 3

6 Authorisation of practitioners to supply pharmaceutical benefits 3

7 Maximum quantity (number of units) 3

Schedule 1—Pharmaceutical benefits that may be supplied by authorised suppliers 4

Part 1—Preliminary

1 Name

(1) This instrument is the *National Health (Prescriber Bag Supplies) Determination 2024*.

(2) This instrument may also be cited as PB 29 of 2024.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | *1 April 2024* | *1 April 2024* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under sections 93 and 93AB of the *National Health Act 1953.*

4 Definitions

Note 1: Under subsection 4(1A) of the Act, a word or phrase defined for the purposes of the *Health Insurance Act 1973* has the meaning that it would have if used in that Act. Expressions used in this instrument that are defined in that Act include ‘medical practitioner’.

In this instrument:

***Act*** means the *National Health Act 1953*.

***authorised nurse practitioner*** has the same meaning as in Part VII of the Act.

***pharmaceutical benefit***has the same meaning as in Part VII of the Act.

***pharmaceutical benefit has a drug***has the same meaning as in Part VII of the Act.

***pharmaceutical benefit that has a drug in a relevant form***: see section 5.

5 References to a pharmaceutical benefit that has a drug in a relevant form

A reference in this instrument to a pharmaceutical benefit that has a drug in a relevant form is a reference to a pharmaceutical benefit that has a drug mentioned in an item in Schedule 1 in the column headed “Listed Drug” in the form mentioned for that drug in the column in Schedule 1 headed “Form”.

Part 2—Authorisation of practitioners and maximum quantity (number of units)

6 Authorisation of practitioners to supply pharmaceutical benefits

(1) For the purposes of subsection 93(1) of the Act, a medical practitioner is authorised to supply a pharmaceutical benefit that has a drug in a relevant form if the initials “MP” are mentioned for that drug in that form in the column in Schedule 1 headed “Prescriber Bag Supplier”.

(2) For the purposes of subsection 93AB(1) of the Act, an authorised nurse practitioner is authorised to supply a pharmaceutical benefit that has a drug in a relevant form if the initials “NP” are mentioned for that drug in that form in the column in Schedule 1 headed “Prescriber Bag Supplier”.

7 Maximum quantity (number of units)

(1) This section determines the maximum number of units of a pharmaceutical benefit that has a drug in a relevant form which may be obtained by a medical practitioner or an authorised nurse practitioner (a ***practitioner***) in a calendar month for the purposes of subsection 93(2) and subsection 93AB(2) of the Act.

(2) The maximum number of units is the number of units mentioned in the column in Schedule 1 headed “Maximum Quantity” for that drug in that form.

(3) Despite subsection (2), if a practitioner has already obtained 1 or more units of a pharmaceutical benefit that has a drug in a relevant form in a group in the same calendar month, the maximum number of units of any other pharmaceutical benefit that has a drug in a relevant form in that group is zero for that calendar month.

(4) For this section, a ***group*** is each pharmaceutical benefit that has a drug in a relevant form which has the same number mentioned for the drug and form in the column in Schedule 1 headed “Group Number”.

Schedule 1—Pharmaceutical benefits that may be supplied by authorised suppliers

| **Group Number** | **Listed Drug** | **Form** | **Prescriber Bag Supplier** | **Maximum Quantity** |
| --- | --- | --- | --- | --- |
| **1** | Adrenaline (epinephrine) | Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000) | MP, NP | 5 |
| **3** | Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | MP, NP | 10 |
| **58** | Benzathine benzylpenicillin | Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre‑filled syringe | MP, NP | 10 |
| **58** | Benzathine benzylpenicillin | Powder for injection 1,200,000 units with diluent 5 mL (S19A) | MP, NP | 10 |
| **31** | Benzatropine | Injection containing benzatropine mesilate 2 mg in 2 mL | MP, NP | 5 |
| **17** | Benzylpenicillin | Powder for injection 600 mg (as sodium) | MP, NP | 5 |
| **32** | Benzylpenicillin | Powder for injection 3 g (as sodium) | MP, NP | 1 |
| **4** | Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | MP, NP | 10 |
| **34** | Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | MP, NP | 1 |
| **25** | Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre‑filled syringe | MP, NP | 10 |
| **10** | Furosemide | Injection 20 mg in 2 mL | MP, NP | 5 |
| **60** | Furosemide | Tablet 20 mg | MP, NP | 50 |
| **26** | Glucagon | Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | MP, NP | 1 |
| **26** | Glucagon | Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe (s19A) | MP, NP | 1 |
| **30** | Glyceryl Trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | MP, NP | 1 |
| **4** | Haloperidol | Injection 5 mg in 1 mL | MP, NP | 10 |
| **12** | Hydrocortisone | Injection 100 mg (as sodium succinate) with 2 mL solvent | MP, NP | 2 |
| **12** | Hydrocortisone | Injection 250 mg (as sodium succinate) with 2 mL solvent | MP, NP | 1 |
| **33** | Hyoscine | Injection containing hyoscine butylbromide 20 mg in 1 mL | MP, NP | 5 |
| **54** | Lidocaine | Injection containing lidocaine hydrochloride monohydrate 50 mg in 5 mL | MP, NP | 5 |
| **35** | Methoxyflurane | Liquid for inhalation 999 mg per g, 3 mL (with inhaler) | MP | 1 |
| **18** | Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | MP, NP | 10 |
| **53** | Midazolam | Injection 5 mg (as hydrochloride) in 1 mL | MP, NP | 10 |
| **62** | Molnupiravir | Capsule 200 mg | MP, NP | 80 |
| **14** | Morphine | Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL | MP, NP | 5 |
| **14** | Morphine | Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL | MP, NP | 5 |
| **14** | Morphine | Injection containing morphine sulfate pentahydrate 15 mg in 1 mL | MP, NP | 5 |
| **14** | Morphine | Injection containing morphine sulfate pentahydrate 30 mg in 1 mL | MP, NP | 5 |
| **57** | Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | MP, NP | 10 |
| **61** | Nirmatrelvir and ritonavir | Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5 | MP, NP | 2 |
| **55** | Phytomenadione | Injection 10 mg in 1 mL | MP | 5 |
| **17** | Procaine benzylpenicillin | Injection 1.5 g in disposable syringe | MP, NP | 5 |
| **18** | Prochlorperazine | Injection containing prochlorperazine mesilate 12.5 mg in 1 mL | MP, NP | 10 |
| **19** | Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | MP, NP | 10 |
| **59** | Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | MP, NP | 1 |
| **59** | Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 (S19A) | MP, NP | 1 |
| **59** | Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | MP, NP | 1 |
| **28** | Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | MP, NP | 1 |
| **28** | Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | MP, NP | 1 |
| **59** | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | MP, NP | 1 |
| **16** | Tramadol | Injection containing tramadol hydrochloride 100 mg in 2 mL | MP, NP | 5 |